Wave Life Sciences, Inc. business relationships
Companies named in Wave Life Sciences, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Wave Life Sciences, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in Wave Life Sciences, Inc.’s annual report 4
“In February 2018, the Company entered into a global strategic collaboration with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company agreed to collaborate with Takeda on the research, development and commercialization of oligonucleotide therapeutics for disorders of the c...” SEC filing
“...accordance with ASC 606, Revenue from Contracts with Customers ("ASC 606") and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term.” SEC filing
“Collaboration and License Agreement by and between Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GlaxoSmithKline Intellectual Property (No. 3), dated as of December 13, 2022” SEC filing
“GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.” SEC filing
Companies whose annual reports name Wave Life Sciences, Inc. 1
“...rapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences Ltd., as well as our collaborators Regeneron, Roche, Sanofi and Vir.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.